Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets

Abstract

2  DELSA/HEA/WD/HWP(2022)14 Unclassified OECD Health Working papers http://www.oecd.org/els/health-systems/health-working-papers.htm OECD Working Papers should not be reported as representing the official views of the OECD or of its member countries. The opinions expressed and arguments employed are those of the author(s).Working Papers describe preliminary results or research in progress by the author(s) and are published to stimulate discussion on a broad range of issues on which the OECD works. Comments on Working Papers are welcomed, and may be sent to

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs

“…In an ideal world, these objectives could be achieved simultaneously, but, in the real world, several factors can undermine this possibility. For this reason, healthcare regulators use a wide range of policies, often in combination, resulting in a system that is not transparent and, in any case, not efficient in optimising both access and innovation in the long run [ 14 , 15 ].…”

“…Pricing policies across countries are heterogeneous, ranging from direct pricing (as in Italy and France) to indirect regulation (as in Germany and Japan) and profit control [ 11 , 12 , 13 , 14 ]. Also, countries often use more than one method at the same time, leading to pricing systems that lack transparency [ 15 ].…”